Cited 0 time in
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Francisco Ugarte-Gil, Manuel | - |
| dc.contributor.author | Hanly, John | - |
| dc.contributor.author | Urowitz, Murray | - |
| dc.contributor.author | Gordon, Caroline | - |
| dc.contributor.author | Bae, Sang-Cheol | - |
| dc.contributor.author | Romero-Diaz, Juanita | - |
| dc.contributor.author | Sanchez-Guerrero, Jorge | - |
| dc.contributor.author | Bernatsky, Sasha | - |
| dc.contributor.author | Clarke, Ann Elaine | - |
| dc.contributor.author | Wallace, Daniel J. | - |
| dc.contributor.author | Isenberg, David Alan | - |
| dc.contributor.author | Rahman, Anisur | - |
| dc.contributor.author | Merrill, Joan T. | - |
| dc.contributor.author | Fortin, Paul R. | - |
| dc.contributor.author | Gladman, Dafna D. | - |
| dc.contributor.author | Bruce, Ian N. | - |
| dc.contributor.author | Petri, Michelle | - |
| dc.contributor.author | Ginzler, Ellen M. | - |
| dc.contributor.author | Dooley, Mary Anne | - |
| dc.contributor.author | Ramsey-Goldman, Rosalind | - |
| dc.contributor.author | Manzi, Susan | - |
| dc.contributor.author | Jonsen, Andreas | - |
| dc.contributor.author | van Vollenhoven, Ronald F. | - |
| dc.contributor.author | Aranow, Cynthia | - |
| dc.contributor.author | Mackay, Meggan | - |
| dc.contributor.author | Ruiz-Irastorza, Guillermo | - |
| dc.contributor.author | Lim, Sam | - |
| dc.contributor.author | Inanc, Murat | - |
| dc.contributor.author | Kalunian, Ken | - |
| dc.contributor.author | Jacobsen, Soren | - |
| dc.contributor.author | Peschken, Christine | - |
| dc.contributor.author | Kamen, Diane L. | - |
| dc.contributor.author | Askanase, Anca | - |
| dc.contributor.author | Pons-Estel, Bernardo A. | - |
| dc.contributor.author | Alarcon, Graciela S. | - |
| dc.date.accessioned | 2023-07-05T03:50:52Z | - |
| dc.date.available | 2023-07-05T03:50:52Z | - |
| dc.date.issued | 2022-11 | - |
| dc.identifier.issn | 0003-4967 | - |
| dc.identifier.issn | 1468-2060 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/186176 | - |
| dc.description.abstract | Objective To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual. Methods Patients with >= 2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined: remission off-treatment: clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment: cSLEDAI-2K score=0, prednisone <= 5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC): cSLEDAI-2K score of <= 2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS): Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone <= 7.5 mg/day and/or maintenance immunosuppressants; active: all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit. Results There were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment: incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment: IRR=0.68, 95% CI 0.62 to 0.75; LDA: IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS: IRR=0.76, 95% CI 0.65 to 0.89)). Conclusions Remission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers. | - |
| dc.format.extent | 8 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | BMJ Publishing Group | - |
| dc.title | Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1136/ard-2022-222487 | - |
| dc.identifier.scopusid | 2-s2.0-85136542044 | - |
| dc.identifier.wosid | 000838791500001 | - |
| dc.identifier.bibliographicCitation | Annals of the Rheumatic Diseases, v.81, no.11, pp 1541 - 1548 | - |
| dc.citation.title | Annals of the Rheumatic Diseases | - |
| dc.citation.volume | 81 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 1541 | - |
| dc.citation.endPage | 1548 | - |
| dc.type.docType | Article; Early Access | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Rheumatology | - |
| dc.relation.journalWebOfScienceCategory | Rheumatology | - |
| dc.subject.keywordPlus | ACTIVITY STATE | - |
| dc.subject.keywordPlus | PROLONGED REMISSION | - |
| dc.subject.keywordPlus | INITIAL VALIDATION | - |
| dc.subject.keywordPlus | CAUCASIAN PATIENTS | - |
| dc.subject.keywordPlus | PREVALENCE | - |
| dc.subject.keywordPlus | LUMINA | - |
| dc.subject.keywordPlus | SLE | - |
| dc.subject.keywordPlus | DEFINITIONS | - |
| dc.subject.keywordPlus | PREDNISONE | - |
| dc.subject.keywordPlus | CATARACTS | - |
| dc.subject.keywordAuthor | systemic lupus erythematosus | - |
| dc.subject.keywordAuthor | outcome assessment | - |
| dc.subject.keywordAuthor | health care | - |
| dc.subject.keywordAuthor | epidemiology | - |
| dc.identifier.url | https://ard.bmj.com/content/early/2022/08/09/ard-2022-222487 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
